gemcitabine has been researched along with urea in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (12.00) | 29.6817 |
| 2010's | 22 (88.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Honsova, E; Kocik, M; Kriz, J; Kudla, M; Mergental, H; Pantoflicek, T; Ryska, M; Saudek, F; Tcherentsova, K | 1 |
| Darro, F; Dewelle, J; Dumont, P; El Yazidi, M; Gaussin, JF; Kiss, R; Lefranc, F; Mahieu, T; Mijatovic, T; Ribaucour, F; Sauvage, S; Simon, G; Tuti, J; Van Quaquebeke, E; Van Vynckt, F | 1 |
| Ashwell, S; Caleb, BL; Deng, C; Green, S; Grondine, MR; Haye, HR; Horn, CL; Janetka, JW; Liu, D; Mouchet, E; Queva, C; Ready, S; Rosenthal, JL; Schwartz, GK; Sheehy, AM; Taylor, KJ; Tse, AN; Walker, GE; White, AM; Zabludoff, SD | 1 |
| Conti, C; McNeely, S; Patel, H; Pommier, Y; Schwartz, G; Sheikh, T; Tse, A; Zabludoff, S | 1 |
| Arumugarajah, S; Canman, CE; Davis, MA; Hassan, MC; Hylander-Gans, L; Lawrence, TS; Maybaum, J; Morgan, MA; Morosini, D; Normolle, DP; Parsels, JD; Parsels, LA; Simeone, DM; Zabludoff, SD; Zhao, L | 1 |
| Lawrence, TS; Maybaum, J; Morgan, MA; Normolle, D; Parsels, LA; Zhao, L | 1 |
| Cheung, IY; Cheung, NK; Gao, X; Tran, H; Wei, XX; Xu, H | 1 |
| Arumugarajah, S; Brown, JL; Gross, M; Hassan, MC; Hylander-Gans, L; Lawrence, TS; Maybaum, J; Morgan, MA; Morosini, D; Parsels, JD; Parsels, LA; Qian, Y; Simeone, DM; Tanska, DM; Zabludoff, SD; Zhao, L | 1 |
| Ishigaki, Y; Kawakami, K; Kitano, A; Minamoto, T; Motoo, Y; Nakajima, H; Nakamura, Y; Nakaya, N; Sato, I; Shimasaki, T; Takata, T; Takegami, T; Tanaka, T; Tomosugi, N; Zhao, X | 1 |
| Almeida, L; Ashwell, S; Brassil, P; Breed, J; Deng, C; Gero, T; Grondine, M; Horn, C; Ioannidis, S; Janetka, J; Liu, D; Lyne, P; Newcombe, N; Oza, V; Pass, M; Read, J; Ready, S; Rowsell, S; Su, M; Toader, D; Vasbinder, M; Xue, Y; Yu, D; Yu, Y; Zabludoff, S | 1 |
| Aarts, M; Ashworth, A; Garcia-Murillas, I; Gevensleben, H; Hurd, MS; Sharpe, R; Shumway, SD; Toniatti, C; Turner, NC | 1 |
| Campbell, C; Dwivedi, P; Garg, NK; Tyagi, RK | 1 |
| Bepler, G; Chen, Z; Li, X; Malysa, A; Oliveira, P; Zhang, Y; Zhou, J | 1 |
| Agbo, F; Arita, S; Esaki, T; Fujimoto, C; Hamatake, M; Hirai, F; Kometani, T; Makiyama, A; Nosaki, K; Seto, T; Shi, X; Takeoka, H | 1 |
| Beer, DG; Bergeron, EJ; Chen, G; Giordano, TJ; Grabauskiene, S; Morgan, MA; Reddy, RM; Thomas, DG | 1 |
| Agbo, F; Azad, N; Barker, P; Carducci, M; Carter, J; Cosgrove, D; Knight, R; Lorusso, P; Malburg, L; Oakes, P; Quinn, MF; Sausville, E; Senderowicz, A; Zabludoff, S | 1 |
| Bryant, C; Massey, AJ; Rawlinson, R | 1 |
| Kwiatkowski, DJ; Liu, Y | 1 |
| Brown, K; Linclau, B; Weymouth-Wilson, A | 1 |
| Gao, S; Hedrick, JL; Krishnamurthy, S; Ng, VW; Tan, MH; Yang, YY | 1 |
| Cuneo, KC; Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Tanska, DM; Zabludoff, SD | 1 |
| Green, JE; He, S; Min, DJ | 1 |
| Cinatl, J; Hoffmann, MJ; Isono, M; Michaelis, M; Niegisch, G; Pinkerneil, M; Sato, A; Schulz, WA | 1 |
| Aguilar-Bonavides, C; Behrens, C; Çeliktas, M; Delgado, O; Dennison, JB; Dhillon, D; Do, KA; Fahrmann, JF; Gazdar, AF; Hanash, SM; Ostrin, EJ; Taguchi, A; Tanaka, I; Tripathi, SC; Villalobos, P; Wang, H | 1 |
| Benes, C; Gao, P; Gray, NS; Li, F; Li, Y; Liu, F; Liu, Q; Liu, Y; Merlino, AA; Quinn, MM; Wang, X; Wong, KK | 1 |
2 trial(s) available for gemcitabine and urea
| Article | Year |
|---|---|
Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases; Thiophenes; Urea | 2013 |
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Protein Kinases; Thiophenes; Urea | 2014 |
23 other study(ies) available for gemcitabine and urea
| Article | Year |
|---|---|
Gemcitabine does not prevent acute rejection of the transplanted liver in rats.
Topics: Acute Disease; Animals; Creatinine; Cyclosporine; Deoxycytidine; Gemcitabine; Graft Rejection; Immunosuppressive Agents; Liver; Liver Transplantation; Male; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Treatment Failure; Urea | 2005 |
2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity.
Topics: Acetamides; Adenine; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Camptothecin; Cell Line, Tumor; Cellular Senescence; Deoxycytidine; Drug Screening Assays, Antitumor; Erythrocyte Count; Female; Gemcitabine; Humans; Imides; Irinotecan; Isoquinolines; Leukocyte Count; Maximum Tolerated Dose; Mice; Naphthalimides; Neoplasm Transplantation; Organophosphonates; Platelet Count; Structure-Activity Relationship; Topoisomerase I Inhibitors; Urea | 2007 |
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
Topics: Animals; Biological Assay; Cell Cycle Proteins; Cell Death; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Synergism; G2 Phase; Gemcitabine; HCT116 Cells; HT29 Cells; Humans; Male; Mice; Mutation; Protein Kinase Inhibitors; Protein Kinases; Rats; Thiophenes; Topotecan; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2008 |
Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Comet Assay; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Repair; DNA-Activated Protein Kinase; DNA-Binding Proteins; G1 Phase; Gemcitabine; Histones; Humans; Mitosis; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; S Phase; Thiophenes; Tumor Suppressor Proteins; Urea | 2010 |
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; DNA Damage; DNA Repair; Drug Therapy, Combination; Flow Cytometry; Fluorescent Antibody Technique; G2 Phase; Gamma Rays; Gemcitabine; Humans; Immunoblotting; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Rad51 Recombinase; Radiation-Sensitizing Agents; Recombination, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2010 |
Bayesian hierarchical changepoint methods in modeling the tumor growth profiles in xenograft experiments.
Topics: Animals; Bayes Theorem; Cell Proliferation; Confidence Intervals; Deoxycytidine; Gemcitabine; Mice; Models, Biological; Models, Statistical; Neoplasms; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2011 |
Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neuroblastoma; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2011 |
Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
Topics: Animals; Biomarkers; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Gemcitabine; Histones; Humans; Mice; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Thiophenes; Transplantation, Heterologous; Urea; Xenograft Model Antitumor Assays | 2011 |
Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Urea; Xenograft Model Antitumor Assays | 2012 |
Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.
Topics: Animals; Antineoplastic Agents; Binding Sites; Camptothecin; Checkpoint Kinase 1; Crystallography, X-Ray; Deoxycytidine; DNA Damage; Drug Design; Drug Synergism; Gemcitabine; High-Throughput Screening Assays; Irinotecan; Mice; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Rats; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2012 |
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Checkpoint Kinase 1; Cyclins; Deoxycytidine; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Mitosis; Nuclear Proteins; Polycomb Repressive Complex 2; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Quinolines; S Phase; Thiazoles; Thiophenes; Transcription Factors; Tumor Burden; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2012 |
Site specific/targeted delivery of gemcitabine through anisamide anchored chitosan/poly ethylene glycol nanoparticles: an improved understanding of lung cancer therapeutic intervention.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Benzamides; Cell Line, Tumor; Chitosan; Deoxycytidine; Drug Carriers; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Polyethylene Glycols; Tissue Distribution; Urea | 2012 |
A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
Topics: Animals; Cattle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Small Molecule Libraries; Thiophenes; Treatment Outcome; Tumor Suppressor Proteins; Urea | 2013 |
Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Protein Kinases; Thiophenes; Urea | 2014 |
Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Topics: Benzodiazepinones; Biomarkers, Tumor; Cell Line, Tumor; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Indoles; MCF-7 Cells; Ovarian Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridones; Thiophenes; Triple Negative Breast Neoplasms; Urea | 2014 |
Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Mutation; Protein Kinases; Pyrazoles; Thiophenes; Tumor Suppressor Protein p53; Urea; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
A linear synthesis of gemcitabine.
Topics: Acylation; Antimetabolites, Antineoplastic; Catalysis; Cyclization; Deoxycytidine; Gemcitabine; Urea | 2015 |
Codelivery of dual drugs from polymeric micelles for simultaneous targeting of both cancer cells and cancer stem cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Synergism; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Micelles; Neoplastic Stem Cells; Phenformin; Polycarboxylate Cement; Polyethylene Glycols; Urea | 2015 |
Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Cyclin B1; Deoxycytidine; DNA Damage; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Mitosis; Nocodazole; Pancreatic Neoplasms; Thiophenes; Urea | 2016 |
Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Dipeptides; DNA Repair; Female; Gemcitabine; Humans; Indoles; Phosphorylation; Thiophenes; Triple Negative Breast Neoplasms; Urea | 2016 |
Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; DNA Damage; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; RNA, Small Interfering; Thiophenes; Urea; Urinary Bladder Neoplasms | 2017 |
Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.
Topics: Adenocarcinoma; Aged; AMP-Activated Protein Kinase Kinases; Carbamoyl-Phosphate Synthase (Ammonia); Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metabolic Networks and Pathways; Metabolome; Middle Aged; Pemetrexed; Prognosis; Proportional Hazards Models; Protein Serine-Threonine Kinases; Proteome; RNA, Messenger; Signal Transduction; Survival Rate; Thiophenes; Tissue Array Analysis; Urea | 2017 |
Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
Topics: Adenocarcinoma; AMP-Activated Protein Kinase Kinases; Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Knockout; Mice, Nude; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Thiophenes; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2017 |